Is Philip Morris Stock Overvalued?
If there is one industry that can be termed truly…
Sell
45
COR Quote, Financials, Valuation and Earnings
Last price:
$246.28
Seasonality move
:
2.76%
Day range:
$242.48 - $245.36
52-week range:
$214.77 - $253.27
Dividend yield:
0.85%
P/E ratio:
32.63x
P/S ratio:
0.17x
P/B ratio:
73.33x
Volume:
1.2M
Avg. volume:
1.2M
1-year change:
12.27%
Market cap:
$47.4B
Revenue:
$294B
EPS (TTM):
$7.51
Analysts' Opinion
-
Consensus RatingCencora has received a consensus rating of Buy. The company's average rating is a Buy based on 9 Buy ratings, 6 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $267.88, Cencora has an estimated upside of 9.31% from its current price of $245.07.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $230.00 representing 6.15% downside risk from its current price of $245.07.
Fair Value
-
According to the consensus of 15 analysts, Cencora has 9.31% upside to fair value with a price target of $267.88 per share.
COR vs. S&P 500
-
Over the past 5 trading days, Cencora has overperformed the S&P 500 by 1.88% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Cencora does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Cencora has grown year-over-year revenues for 49 quarters straight. In the most recent quarter Cencora reported revenues of $79.1B.
Earnings Growth
-
Cencora earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Cencora reported earnings per share of $0.02.
Enterprise value:
48.8B
EV / Invested capital:
--
Price / LTM sales:
0.17x
EV / EBIT:
21.65x
EV / Revenue:
0.17x
PEG ratio (5yr expected):
2.14x
EV / Free cash flow:
16.27x
Price / Operating cash flow:
16.37x
Enterprise value / EBITDA:
14.46x
Gross Profit (TTM):
$9.9B
Return On Assets:
2.32%
Net Income Margin (TTM):
0.51%
Return On Equity:
157.14%
Return On Invested Capital:
26.26%
Operating Margin:
0.92%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $238.6B | $262.2B | $294B | $68.9B | $79.1B | |
| Gross Profit | $8.3B | $9B | $9.9B | $2.3B | $2.5B | |
| Operating Income | $2.8B | $2.7B | $3.2B | $583.4M | $725M | |
| EBITDA | $3.1B | $3.4B | $3.4B | $804.2M | $459.2M | |
| Diluted EPS | $8.04 | $8.53 | $7.51 | $1.72 | $0.02 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $33.1B | $38.8B | $39.6B | $42.8B | $47.7B | |
| Total Assets | $44.3B | $57.3B | $56.6B | $62.6B | $67.1B | |
| Current Liabilities | $33.9B | $41.4B | $43.5B | $48.8B | $54.3B | |
| Total Liabilities | $45.1B | $56.8B | $56.5B | $61.9B | $66.3B | |
| Total Equity | -$839.6M | $584.4M | $71.3M | $666.3M | $786.7M | |
| Total Debt | $4.1B | $6.7B | $5.7B | $4.8B | $4.4B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $2.7B | $3.9B | $3.5B | $1.8B | $1B | |
| Cash From Investing | -$368.4M | -$2.6B | -$618.1M | -$183.4M | -$241.9M | |
| Cash From Financing | -$1.8B | -$2.2B | -$2.3B | -$407M | -$957.3M | |
| Free Cash Flow | $2.2B | $3.5B | $3B | $1.7B | $818.1M | |
COR
Sector
Market Cap
$47.4B
$45.7M
Price % of 52-Week High
96.76%
47.48%
Dividend Yield
0.85%
0%
Shareholder Yield
4.59%
-0.75%
1-Year Price Total Return
12.27%
-32.34%
Beta (5-Year)
0.487
0.746
Dividend yield:
0.85%
Annualized payout:
$2.04
Payout ratio:
27.58%
Growth streak:
19 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$239.48
200-day SMA
Buy
Level
$233.01
Bollinger Bands (100)
Buy
Level
226.41 - 243.35
Chaikin Money Flow
Buy
Level
392.9M
20-day SMA
Buy
Level
$232.25
Relative Strength Index (RSI14)
Buy
Level
67.90
ADX Line
Buy
Level
26.35
Williams %R
Sell
Level
-1.3526
50-day SMA
Buy
Level
$238.48
MACD (12, 26)
Buy
Level
1.91
25-day Aroon Oscillator
Buy
Level
48
On Balance Volume
Neutral
Level
340.7M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (4.8843)
Sell
CA Score
(Annual)
Level (-0.7789)
Buy
Beneish M-Score
(Annual)
Level (-2.5284)
Buy
Momentum Score
Level (7)
Sell
Ohlson Score
Level (2.0641)
Buy
Piotroski F Score
(Annual)
Level (7)
Sell
Quality Ratio Score
Level (3)
Buy
Fundamental Score
Level (6)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Cencora is one of three domestic leading pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health constitute over 90% of the us pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.
Stock Forecast FAQ
In the current month, COR has received 9 Buy ratings 6 Hold ratings, and 0 Sell ratings. The COR average analyst price target in the past 3 months is $267.88.
-
Where Will Cencora Stock Be In 1 Year?
According to analysts, the consensus estimate is that Cencora share price will rise to $267.88 per share over the next 12 months.
-
What Do Analysts Say About Cencora?
Analysts are divided on their view about Cencora share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Cencora is a Sell and believe this share price will drop from its current level to $230.00.
-
What Is Cencora's Price Target?
The price target for Cencora over the next 1-year time period is forecast to be $267.88 according to 15 Wall Street analysts, 9 of them rate the stock a Buy, 0 rate the stock a Sell, and 6 analysts rate the stock a Hold.
-
Is COR A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Cencora is a Buy. 9 of 15 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of COR?
You can purchase shares of Cencora via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Cencora shares.
-
What Is The Cencora Share Price Today?
Cencora was last trading at $246.28 per share. This represents the most recent stock quote for Cencora. Yesterday, Cencora closed at $245.07 per share.
-
How To Buy Cencora Stock Online?
In order to purchase Cencora stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
What Quantum Stocks Should I Buy?
The last several years have seen a series of tech…
Will Sirius XM Be a 10-Bagger Stock?
Last year, Warren Buffett surprised practically everyone when he acquired…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Sell
43
Is AAPL Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Buy
51
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 36x
Alerts
Sell
32
FTAI alert for Jan 22
FTAI Aviation [FTAI] is up 7.77% over the past day.
Sell
2
EDU alert for Jan 22
New Oriental Education & Technology Group [EDU] is down 0.45% over the past day.
Buy
51
GH alert for Jan 22
Guardant Health [GH] is up 5.69% over the past day.
